Omics Sequencing of Specimen Derived From Mother-Infant-Pairs
Launched by ZHUJIANG HOSPITAL · Jul 13, 2022
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the makeup of breast milk and feces from healthy mother-infant pairs. Researchers want to collect these samples and use advanced technology to analyze the bacteria and other tiny substances present. This research aims to better understand how these factors might affect health and development in infants.
To participate in the trial, mothers need to be healthy, between the ages of 20 and 40, and have had a vaginal birth. They should also have a body mass index (BMI) of less than 23.5 before pregnancy, and their infants should weigh between 2500 grams and 4000 grams at birth. Participants can expect to provide samples of breast milk and feces, which will be carefully analyzed. It's important to know that certain health conditions, like gestational diabetes or high blood pressure during pregnancy, as well as recent use of antibiotics or probiotics, could prevent someone from joining the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • healthy pregnant women aged between 20y and 40y.
- • Vaginal birth
- • BMI\<23.5 before pregnancy
- • Infants' birth weight, between 2500g and 4000g.
- Exclusion Criteria:
- • gestational diabetes
- • diagnosis of depressive disorder during pregnancy
- • gestational hypertension
- • diagnosis of other diseases during pregnancy
- • Under probiotics or antibiotic treatment from 3 months prior to pregnancy till 3 months after delivery
- • histrory of smoking and drinking alcohol
- • history of diarrhea from 3 months prior to pregnancy till 3 months after delivery
About Zhujiang Hospital
Zhujiang Hospital, affiliated with the Southern Medical University in Guangzhou, China, is a leading clinical research institution dedicated to advancing medical science and improving patient care through rigorous clinical trials. With a strong commitment to ethical standards and patient safety, the hospital boasts a multidisciplinary team of experienced researchers and healthcare professionals. Its state-of-the-art facilities enable the execution of innovative studies across various therapeutic areas, contributing valuable insights to the global medical community. Zhujiang Hospital aims to foster collaboration with academic institutions, pharmaceutical companies, and regulatory bodies to ensure the successful development of new therapies and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials